Verinurad is primarily used in the treatment of hyperuricemia and gout. It functions as a selective uric acid reabsorption inhibitor, targeting the URAT1 transporter in the kidneys to enhance uric acid excretion. This helps in lowering serum uric acid levels, preventing the formation of urate crystals that lead to gout attacks. It is often studied in combination with xanthine oxidase inhibitors for more effective management of chronic gout. Its application is significant for patients who do not respond adequately to traditional therapies, offering a targeted approach to improve long-term outcomes.